Overview

Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
ZARS Pharma Inc.
Treatments:
Lidocaine
Tetracaine
Criteria
Inclusion Criteria:

- be at least 18 years of age

- have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3
myofascial trigger points

- have trigger points confined to the upper back, shoulder, and neck

Exclusion Criteria:

- have used any topically applied pain medication on the target treatment area within 3
days preceding the Screening/Baseline Visit

- have used any topically applied pain medication on the target treatment area within 3
days preceding the Screening/Baseline Visit

- have used any injected pain medication with 28 days preceding the Screening/Baseline
Visit

- are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine, etc.)

Other protocol-defined inclusion/exclusion criteria may apply.